210 related articles for article (PubMed ID: 29027612)
21. HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.
Alzahrani AS; Murugan AK; Qasem E; Al-Hindi H
Thyroid; 2016 May; 26(5):667-71. PubMed ID: 26906432
[TBL] [Abstract][Full Text] [Related]
22. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and Management of Hereditary Thyroid Cancer.
Bano G; Hodgson S
Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
[TBL] [Abstract][Full Text] [Related]
24. Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
Majdalani P; Yoel U; Nasasra T; Fraenkel M; Haim A; Loewenthal N; Zarivach R; Hershkovitz E; Parvari R
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175943
[TBL] [Abstract][Full Text] [Related]
25. Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients.
Capezzone M; Sagnella A; Cantara S; Fralassi N; Maino F; Forleo R; Brilli L; Pilli T; Cartocci A; Castagna MG
Front Endocrinol (Lausanne); 2022; 13():845954. PubMed ID: 35311228
[TBL] [Abstract][Full Text] [Related]
26. The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma -- only phenotype with incomplete penetrance: implications for screening and management of carrier status.
Dabir T; Hunter SJ; Russell CF; McCall D; Morrison PJ
Fam Cancer; 2006; 5(2):201-4. PubMed ID: 16736292
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
28. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
Hińcza K; Kowalik A; Kowalska A
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
[TBL] [Abstract][Full Text] [Related]
29. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers].
Kazubskaia TP; Kozlova VM; Kondrat'eva TT; Pavlovskaia AI; Marakhonov AV; Baranova AV; Ivanova NI; Stepanova AA; Poliakov AV; Belev NF; Brzhezovskiĭ VZh
Arkh Patol; 2014; 76(5):3-12. PubMed ID: 25543402
[TBL] [Abstract][Full Text] [Related]
30. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
[No Abstract] [Full Text] [Related]
31. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Cancer Control; 2006 Apr; 13(2):106-10. PubMed ID: 16735984
[TBL] [Abstract][Full Text] [Related]
32. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
[TBL] [Abstract][Full Text] [Related]
33. Penetrance and clinical manifestations of non-hotspot germline RET mutation, C630R, in a family with medullary thyroid carcinoma.
Dourisboure RJ; Belli S; Domenichini E; Podestá EJ; Eng C; Solano AR
Thyroid; 2005 Jul; 15(7):668-71. PubMed ID: 16053382
[TBL] [Abstract][Full Text] [Related]
34. Establishing a familial basis for papillary thyroid carcinoma using the Utah Population Database.
Oakley GM; Curtin K; Pimentel R; Buchmann L; Hunt J
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1171-4. PubMed ID: 24092278
[TBL] [Abstract][Full Text] [Related]
35. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
Xing M
Clin Endocrinol (Oxf); 2005 Sep; 63(3):263-6. PubMed ID: 16117812
[TBL] [Abstract][Full Text] [Related]
36. Germline Mutations in Familial Papillary Thyroid Cancer.
Sarquis M; Moraes DC; Bastos-Rodrigues L; Azevedo PG; Ramos AV; Reis FV; Dande PV; Paim I; Friedman E; De Marco L
Endocr Pathol; 2020 Mar; 31(1):14-20. PubMed ID: 32034658
[TBL] [Abstract][Full Text] [Related]
37. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
[TBL] [Abstract][Full Text] [Related]
38. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Semin Surg Oncol; 1999; 16(1):16-8. PubMed ID: 9890735
[TBL] [Abstract][Full Text] [Related]
39. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
[TBL] [Abstract][Full Text] [Related]
40. Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.
Colombo C; Muzza M; Proverbio MC; Ercoli G; Perrino M; Cirello V; Vicentini L; Ferrero S; Fugazzola L
Clin Endocrinol (Oxf); 2017 Jun; 86(6):837-844. PubMed ID: 28222214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
